文献速递心胸血管麻醉

心脏手术体外循环中肝素敏感性与术后失血的关系

Heparin sensitivity and postoperative blood loss in patients undergoing cardiac surgery with cardiopulmonary bypass.
PubMed 文献 · Eur J Anaesthesiol · 2020-01-01

该前瞻性对照研究纳入195例心脏瓣膜置换术成人患者,按首次肝素2.5 mg/kg后全血活化凝血时间(ACT)分为不敏感组(ACT<480 s)、敏感组(480 s<ACT<750 s)和高敏感组(ACT>750 s)。结果显示敏感组术中及术后24 h失血量较不敏感组和高敏感组低约20%至25%(P<0.01),且肝素敏感性与AT-III及因子X的mRNA和血浆水平相关。

要点

  • 肝素敏感性与心脏术后失血量相关,中等敏感患者术后出血最少。
  • 按首次肝素2.5 mg/kg后ACT值可将患者分为不敏感、敏感和高敏感三组。
  • 肝素敏感性个体差异与AT-III和因子X的mRNA及血浆水平相关。

核心结论

  • 心脏手术患者术后失血与肝素敏感性相关,中等敏感患者术后出血最少。
  • 肝素敏感性的个体差异与AT-III和因子X的mRNA及血浆水平相关。

研究设计与样本

  • 前瞻性对照研究,2016年1月至2018年8月于中国新疆乌鲁木齐三级教学医院开展。
  • 共纳入195例接受心脏瓣膜置换术的成人患者。
  • 首次肝素剂量2.5 mg/kg后按全血ACT分为三组:A组不敏感(ACT<480 s)、B组敏感(480 s<ACT<750 s)、C组高敏感(ACT>750 s)。

主要发现

  • B组术中及术后24 h失血量较A组和C组低约20%至25%,差异有统计学意义(P<0.01)。
  • AT-III mRNA水平从A组到C组升高,与肝素敏感性正相关;因子X mRNA变化方向相反,A组与C组差异有统计学意义(P<0.05)。
  • 因子X血浆水平与其mRNA趋势一致;B组AT-III血浆水平显著低于A组和C组(P<0.05)。

关键数值与推荐

  • 分组标准:首次肝素2.5 mg/kg后ACT<480 s为不敏感,480 s<ACT<750 s为敏感,ACT>750 s为高敏感。
  • 主要结局指标:术中及术后24 h失血量;次要指标包括AT和因子X mRNA水平、AT-III和因子X血浆水平及肝素敏感性指数。

临床怎么用

  • 心脏手术中可根据首次肝素2.5 mg/kg后的ACT值识别肝素敏感性分组,关注中等敏感患者的止血管理。
  • 肝素敏感性个体差异可能与AT-III和因子X的mRNA及血浆水平相关,可作为进一步评估的参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heparin-associated coagulation disorder is an important factor related to postoperative bleeding in patients undergoing cardiac surgery with cardiopulmonary bypass. Currently, the relationship between heparin sensitivity and postoperative bleeding is unknown. OBJECTIVE: To investigate the relationship between individual heparin sensitivity and postoperative blood loss in patients undergoing cardiac surgery. DESIGN: Prospective controlled study. SETTING: Tertiary teaching hospital, Urumqi, Xinjiang, PR China. The study was conducted from January 2016 to August 2018. PATIENTS: A total of 195 adult patients undergoing cardiac valve replacement surgery were included. INTERVENTION: After initial heparin dosing (2.5 mg kg), patients were divided into three groups according to the whole blood activated clotting time (ACT): group A, insensitive group (ACT < 480 s); group B, sensitive group (480 s < ACT < 750 s); group C, hypersensitive group (ACT > 750 s). MAIN OUTCOME MEASURES: First, intra-operative and 24-h postoperative blood loss. Second, antithrombin (AT) and factor X mRNA levels. Third, the plasma levels of AT-III and factor X. Fourth, heparin sensitivity index. RESULTS: Blood loss was approximately 20 to 25% lower in group B than in groups A and C, which was statistically significant (P < 0.01). The AT-III mRNA levels increased from groups A to C and was positively associated with heparin sensitivity; the factor X mRNA levels changed in the opposite direction; a significant difference was observed between groups A and C (P < 0.05). The factor X plasma level showed the same trend as its mRNA. The AT-III plasma level was significantly lower in group B than in groups A and C (P < 0.05). CONCLUSION: Postoperative blood loss is related to heparin sensitivity in patients undergoing cardiac surgery, and the moderately sensitive patients have the least postoperative bleeding. Individual variation in heparin sensitivity is related to the mRNA and plasma levels of AT-III and factor X. TRIAL REGISTRATION: Registration number ChiCTR-RPC-17012259.

来源:Eur J Anaesthesiol,查看原文。版权归原作者所有。

引用

  1. Ma HP, Xu WF, Yu J, et al. Heparin sensitivity and postoperative blood loss in patients undergoing cardiac surgery with cardiopulmonary bypass. Eur J Anaesthesiol. 2020. PMID: 31895135. doi:10.1097/EJA.0000000000001148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。